Global Blood Screening Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

Description

List of Tables

Global Blood Screening Market size is anticipated to grow from USD 3.45 Billion in 2024 to USD 10.06 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 12.62% during the forecast period of 2026 to 2033.

The blood screening market is poised for significant growth, driven by the increasing prevalence of infectious diseases and the rising demand for safe blood transfusions. Blood screening is a critical process that ensures the safety of blood products by detecting pathogens, antibodies, and other harmful substances. As healthcare providers prioritize patient safety and regulatory bodies enforce stringent testing requirements, the adoption of advanced blood screening technologies is expected to rise. This market is witnessing a shift towards more efficient and accurate testing methods, including nucleic acid testing (NAT) and multiplex assays, which enhance the detection capabilities of blood screening processes.

Moreover, advancements in blood screening technologies are propelling innovation within the market. The development of automated systems and point-of-care testing solutions is transforming the way blood screening is conducted, allowing for faster results and improved workflow efficiency. These innovations not only enhance the accuracy of testing but also reduce the turnaround time for results, enabling healthcare providers to make timely decisions regarding patient care. As the blood screening market continues to evolve, ongoing research and development efforts will play a crucial role in expanding the range of testing solutions available to meet the diverse needs of healthcare providers.

Additionally, the growing emphasis on preventive healthcare and early detection is shaping the blood screening landscape. As awareness of the importance of regular health screenings increases, patients are more likely to seek out blood tests that can identify potential health issues before they escalate. Healthcare providers are also recognizing the value of proactive screening in managing chronic conditions and improving patient outcomes. As the blood screening market continues to grow, the combination of technological advancements, increasing patient awareness, and a focus on preventive care will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Technology

Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA & EIA )
Next Generation Sequencing (NGS)
Western Blotting (WB)

By Product

Reagent
Instrument
COMPANIES PROFILED
Abbott
Danaher Corporation (Beckman Coulter)
Becton Dickinson and Company
Bio-Rad Laboratories Inc.
Hoffman-La Roche Ltd.
Grifols
S.A.
Ortho-Clinical Diagnostics Inc.
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
SOFINA SA (Biomerieux)
The above list can be customized.

Product Code: VMR11210532

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BLOOD SCREENING INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porters Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Product
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BLOOD SCREENING MARKET ANALYSIS BY TECHNOLOGY

5.1. Overview By Technology
5.2. Historical and Forecast Data Analysis By Technology
5.3. Nucleic Acid Amplification Test (NAT) Historic and Forecast Sales By Regions
5.4. ELISA Historic and Forecast Sales By Regions
5.5. Chemiluminescence Immunoassay (CLIA & EIA ) Historic and Forecast Sales By Regions
5.6. Next Generation Sequencing (NGS) Historic and Forecast Sales By Regions
5.7. Western Blotting (WB) Historic and Forecast Sales By Regions

6. GLOBAL BLOOD SCREENING MARKET ANALYSIS BY PRODUCT

6.1. Overview By Product
6.2. Historical and Forecast Data Analysis By Product
6.3. Reagent Historic and Forecast Sales By Regions
6.4. Instrument Historic and Forecast Sales By Regions

7. GLOBAL BLOOD SCREENING MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE BLOOD SCREENING COMPANIES

8.1. Blood Screening Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF BLOOD SCREENING INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Danaher Corporation (Beckman Coulter)
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Becton Dickinson And Company
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Bio-Rad Laboratories Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Hoffman-La Roche Ltd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Grifols
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. S.A.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Ortho-Clinical Diagnostics Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Siemens Healthcare GmbH
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Thermo Fisher Scientific Inc.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. SOFINA SA (Biomerieux)
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies